SCHEMBL10162464

SCHEMBL10162464

CC(=O)c1ccc(CNC(=O)c2cc(C(=O)NCc3ccc(F)c(C)c3)nc3ccnn23)cc1

nearest known ligand 0.53

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
MMP13 P45452 10/20 0.53
MMP8 P22894 4/20 0.48
MMP10 P09238 3/20 0.48
MMP9 P14780 1/20 0.48
L3MBTL1 Q9Y468 1/20 0.41
ADAMTS4 O75173 1/20 0.40
MMP3 P08254 1/20 0.40
MMP12 P39900 1/20 0.40
HCRTR1 O43613 1/20 0.39
HCRTR2 O43614 1/20 0.39
MAPK13 O15264 2/20 0.39
MAPK12 P53778 2/20 0.39
MAPK11 Q15759 2/20 0.39
MAPK14 Q16539 2/20 0.39
SMN1; SMN2 Q16637 1/20 0.38
EPHX2 P34913 1/20 0.38
NR1H4 Q96RI1 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8258270 0.93 MMP13 (0.61) MMP13MMP8MMP10MMP9L3MBTL1
SCHEMBL10162426 0.93 MMP13 (0.53) MMP13MMP8MMP10MMP9L3MBTL1
SCHEMBL14449876 0.93 MMP13 (0.58) MMP13MMP8MMP10MMP9L3MBTL1
SCHEMBL10162460 0.92 MMP13 (0.45) MMP13MMP8MMP10MMP9L3MBTL1
SCHEMBL10165643 0.91 MMP13 (0.58) MMP13MMP8MMP10MMP9L3MBTL1
SCHEMBL10162467 0.90 MAPK1 (0.43) MMP13
SCHEMBL10162483 0.89 POLB (0.47) MMP13L3MBTL1SMN1; SMN2
SCHEMBL10162437 0.88 MMP13 (0.47) MMP13MMP8MMP10MMP9ADAMTS4
SCHEMBL8185116 0.87 MMP13 (0.58) MMP13MMP8MMP10MMP9L3MBTL1
SCHEMBL10162440 0.87 POLB (0.45) MMP13MMP8L3MBTL1ADAMTS4MMP3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8835441-B2 Heterobicyclic metalloprotease inhibitors AMGEN INC. (US) 2014-09-16 US disclosed
US-20120015920-A1 HETEROBICYCLIC METALLOPROTEASE INHIBITORS ALANTOS PHARMACEUTICALS HOLDING, INC. (US) 2012-01-19 US disclosed
US-7795245-B2 Heterobicyclic metalloprotease inhibitors Atlantos Pharmaceuticals Holding, Inc. (US) 2010-09-14 US disclosed
US-20090312312-A1 Heterobicyclic Metalloprotease Inhibitors ALANTOS PHARMACEUTICALS HOLDING, INC. (US) 2009-12-17 US disclosed
US-20090137547-A1 Heterobicyclic metalloprotease inhibitors ALANTOS PHARMACEUTICALS HOLDING, INC. 2009-05-28 US disclosed
US-20070155738-A1 Heterobicyclic metalloprotease inhibitors ALANTOS PHARMACEUTICALS, INC. 2007-07-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090312312-A1 Heterobicyclic Metalloprotease Inhibitors MMP13, TIMP3, MMP3 MMP13 1/4885MMP8 26/4885MMP10 4/4885
US-20120015920-A1 HETEROBICYCLIC METALLOPROTEASE INHIBITORS MMP13, TIMP3, MMP3 MMP13 1/4885MMP8 26/4885MMP10 4/4885
US-20090137547-A1 Heterobicyclic metalloprotease inhibitors MMP13, TIMP3, MMP3 MMP13 1/4885MMP8 26/4885MMP10 4/4885
US-20070155738-A1 Heterobicyclic metalloprotease inhibitors MMP13, TIMP3, MMP3 MMP13 1/4885MMP8 26/4885MMP10 4/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.